These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 11103789)

  • 1. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
    Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
    Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
    Liu L; Schwartz S; Davis BM; Gerson SL
    Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
    Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
    Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
    Wedge SR; Porteous JK; Newlands ES
    Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
    Weingart J; Grossman SA; Carson KA; Fisher JD; Delaney SM; Rosenblum ML; Olivi A; Judy K; Tatter SB; Dolan ME
    J Clin Oncol; 2007 Feb; 25(4):399-404. PubMed ID: 17264335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
    Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
    Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
    Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
    Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Felker GM; Friedman HS; Dolan ME; Moschel RC; Schold C
    Cancer Chemother Pharmacol; 1993; 32(6):471-6. PubMed ID: 8258196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo.
    Wan Y; Wu D; Gao H; Lu H
    J Environ Pathol Toxicol Oncol; 2000; 19(1-2):69-75. PubMed ID: 10905510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
    Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
    Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer.
    Phillips WP; Gerson SL
    Cancer Chemother Pharmacol; 1999; 44(4):319-26. PubMed ID: 10447580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
    Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
    Adams DM; Zhou T; Berg SL; Bernstein M; Neville K; Blaney SM;
    Pediatr Blood Cancer; 2008 Mar; 50(3):549-53. PubMed ID: 17941066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
    Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
    Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines.
    Bobola MS; Berger MS; Silber JR
    Mol Carcinog; 1995 Jun; 13(2):81-8. PubMed ID: 7605583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
    Loktionova NA; Pegg AE
    Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
    Rhines LD; Sampath P; DiMeco F; Lawson HC; Tyler BM; Hanes J; Olivi A; Brem H
    Neurosurgery; 2003 Apr; 52(4):872-9; discussion 879-80. PubMed ID: 12657184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
    Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE
    Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.